EP1594479A1 - Compositions orales stables de benzimidazole et leurs procedes de preparation - Google Patents

Compositions orales stables de benzimidazole et leurs procedes de preparation

Info

Publication number
EP1594479A1
EP1594479A1 EP04707268A EP04707268A EP1594479A1 EP 1594479 A1 EP1594479 A1 EP 1594479A1 EP 04707268 A EP04707268 A EP 04707268A EP 04707268 A EP04707268 A EP 04707268A EP 1594479 A1 EP1594479 A1 EP 1594479A1
Authority
EP
European Patent Office
Prior art keywords
composition
core
pharmaceutically acceptable
acceptable excipients
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04707268A
Other languages
German (de)
English (en)
Inventor
Kamal Mehta
Rajeev Shanker Mathur
Sanjeev Kumar Sethi
Rajiv Malik
Shashikanth Isloor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP1594479A1 publication Critical patent/EP1594479A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Definitions

  • the present invention relates to stable oral benzimidazole compositions and processes for their preparation.
  • U.S. Patent Nos. 4,255,431, 4,628,098 and 4,758,579 disclose substituted pyridylsulfinyl benzimidazoles as potent inhibitors of gastric acid secretion.
  • This class of compounds inhibits gastric acid secretion by inhibiting H ⁇ -K "1" ATPase (proton-pump) activity.
  • Drugs in this class are known to be highly unstable in an acidic environment. They are also unstable in the presence of moisture and organic solvents.
  • the formulation in which the drugs are to be administered to a patient, and the process for manufacture of the formulation must be designed to protect the drug from moisture as well as an acidic environment. Due to the rapid drug degradation that occurs in acidic gastric fluids, the formulations may be enteric coated.
  • benzimidazole compounds The stability problems associated with benzimidazole compounds are well recognized in the prior art, which teaches various approaches to preparing stable formulations containing benzimidazole compounds.
  • One of the most common approaches utilized to stabilize benzimidazole compounds is the use of an alkaline core, a separating layer and an enteric coating. It is well-recognized in the art that use of an alkaline medium within the core protects benzimidazole compounds from acid degradation. Previous attempts to stabilize formulations of benzimidazole compounds were ineffective when using an alkaline core without a separating layer between the core and the enteric coating. Thus, the need for a separating layer between the core and enteric coating.
  • U.S. PatentNo. 5,035,899 discloses a peroral preparation of a benzimidazole compound that is described as consisting essentially of a core, a slightly water soluble first coating layer, and a second coating layer.
  • the core contains a pharmacologically effective, acid-unstable benzimidazole compound.
  • the first coating layer is coated on the core and includes a slightly water-soluble, film-forming material selected from the group consisting of ethyl cellulose and polyvinyl acetate and fine particles of a slightly water-soluble substance selected from the group consisting of magnesium oxide, silicic anhydride, calcium silicate, magnesium hydroxide, magnesium carbonate, aluminum hydroxide, calcium stearate, magnesium stearate and sucrose fatty acid esters suspended in the first layer.
  • the second coating layer is coated on the first layer and is made of an enteric polymer film.
  • U.S. Patent No. 6,274,173 discloses a controlled release pharmaceutical composition that includes an acid-labile proton-pump inhibitor other than pantoprazole, an alkaline pellet or tablet core, at least one water-insoluble intermediate layer which controls the release of the active ingredient, and an outer enteric layer which is soluble in the intestine.
  • the subcoating is described as controlling the release of the active ingredient and thereby the active ingredient is released in a modified release manner, i.e., part of the active ingredient is released in immediate manner and part is released in controlled manner.
  • U.S. Patent No. 5,877,192 discloses the use of the (-)-enantiomer of omeprazole (esomeprazole), or a pharmaceutically acceptable salt thereof, in the treatment of gastric acid related diseases as a means to decrease individual variation in plasma levels when compared to omeprazole.
  • the use of the (-)-enantiomer of omeprazole is used to increase the average plasma levels (AUC) of the substance when compared to those of racemic omeprazole; thereby imparting a higher dose efficiency.
  • WO 00/78284 discloses a formulation containing a benzimidazole compound without a separating layer. These formulations disclose the use of a neutralized enteric coating applied as a solution with a pH value of at least 6.5 and more preferably in a range of from about 7 to about 10. The enteric coating is applied directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any need for an intermediate layer.
  • 6,602,522 discloses a stable pharmaceutical composition for an orally administered acid-labile compound used as an active ingredient.
  • the composition includes a tableted core and a single layer of coating on the tableted core, the coating including an enteric coating agent.
  • the tableted core includes an uncoated granulation of a therapeutically effective amount of the active ingredient, an optional surface active agent, a pharmaceutically acceptable alkaline agent, at least one water-soluble binder, and at least one water-insoluble binder.
  • the patent also discloses a tableted core with an alkaline medium and an enteric coating layered directly on the tableted core.
  • U.S. Patent No. 5,385,739 discloses a stable formulation of omeprazole microgranules containing a neutral core of sugar and starch and an active layer consisting of a dilution of omeprazole in mannitol, in substantially equal amounts.
  • the active omeprazole layer contains about 10% by weight of carboxymethylstarch and about 5% by weight of a sodium lauryl sulfate surface-active compound.
  • the dilution of omeprazole in mannitol is applied to the neutral core by means of hydroxypropyl methylcellulose as a high viscosity binder.
  • U.S. Patent No. 5,626,875 discloses the use of an inert sugar/starch spherical core coated with a first layer made up of a mixture of the benzimidazole compound, a water- soluble inert polymer and non-alkaline reacting pharmaceutical acceptable excipients.
  • the first layer is coated with a second isolation layer formed by water-soluble polymers and non- alkaline reacting pharmaceutically accepted excipients.
  • a third layer consisting of an enteric coating is applied over the second layer.
  • U.S. Patent Application No. 20030118650 discloses a tableted oral pharmaceutical dosage form that is covered by an enteric coating and consists of a plurality of units that contain a benzimidazole compound labile in an acid medium as the active principle.
  • the plurality of units contain: i) an inert core; ii) an active layer deposited on the inert core i) and made up of a benzimidazole compound labile in an acid medium, a non-alkaline water-soluble inert polymer and one or more pharmaceutically acceptable inert excipients; and iii) an intermediate layer consisting of an inert non-alkaline coating formed from a non-alkaline, water-soluble inert polymer and one or more pharmaceutically acceptable inert excipients.
  • the intermediate layer is disposed over the active layer ii) that covers the inert core i).
  • U.S. Patent No. 5,626,875 and U.S. Patent Application No. 20030118650 thus use an intermediate layer made of a non-alkaline water-soluble inert polymer along with one or more pharmaceutically acceptable inert excipients.
  • U.S. Patent No. 6,159,499 discloses a composition that is described as being substantially free of alkaline-reacting compounds.
  • the composition includes (a) a core containing an acid-labile benzimidazole active principle; (b) an intermediate layer surrounding the core; and (c) an enteric layer surrounding the intermediate layer.
  • the core includes a plurality of nuclei and the active principle mixed together and then compressed together.
  • the active principle is described as not being in the form of an alkaline salt.
  • This patent also discloses a process for preparing stable oral dosage form of benzimidazole compounds which are free from alkaline reacting compounds.
  • the process includes the steps of (i) mixing a plurality of nuclei with an active principle; (ii) compressing the product of step (i) to form a core comprising the active principle; (iii) coating the core with an intermediate layer; and (iv) coating the product from step (iii) with an enteric layer.
  • U.S. Patent No. 6,207,198 discloses a stable drug composition that includes (a) a core containing an acid-labile omeprazole active principle; (b) an intermediate layer that includes at least one polymer; and (c) an enteric layer.
  • the composition is described as being free of alkaline-reacting compounds.
  • the core is made up of pharmaceutically inert nuclei and the active ingredient, both of which are compressed together.
  • the omeprazole active principle is described as not being in the form of an alkaline salt.
  • the polymer of the intermediate layer is described as being selected from sugars, polyethylene glycol, polyvinylpyrrolidone, poly (vinyl alcohol), hydroxypropylcellulos ⁇ . hydroxymethylcellulose. hydroxypropylmethylcellulose, and mixtures thereof.
  • WO 99/61022 discloses a stable oral pharmaceutical composition in the form of a mixture containing a substituted pyridyl sulfinyl benzimidazole having gastric acid secretion inhibitory activity and a carrier.
  • the carrier includes at least one polymer that is at least partially made up of vinylpyrrolidone monomeric units. Also disclosed is the use of a mixture of benzimidazole compounds with at least one polymer containing vinylpyrrolidone monomeric units, the mixture being free of any alkaline reacting compounds to stabilize benzimidazole compounds.
  • the formulation is in the form of a premix which is not compressed to facilitate the manufacturing operations.
  • U.S. Patent Application 2002128293 teaches a stable oral pharmaceutical composition containing omeprazole and a pharmaceutically acceptable carrier that includes at least one water-insoluble polymer that is at least partially made up of vinylpyrrolidone.
  • the application discloses cross-linked polyvinyl pyrrolidone as the water-insoluble polymer that acts as disintegrant.
  • the inventors have developed a formulation that does not include such a vinylpyrrolidone polymer with disintegrating properties in the separating layer.
  • the present invention relates to the stable oral benzimidazole compositions which overcome the problems associated with prior art.
  • a stable oral benzimidazole pharmaceutical composition includes a core, a separating layer, and an enteric coating.
  • the core includes a benzimidazole compound, a substantially water-soluble material and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is not alkaline.
  • the separating layer surrounds the core and includes a substantially water-soluble material and, optionally, one or more pharmaceutically acceptable excipients.
  • the enteric coating surrounds the separating layer. At least one of the core and the separating layer includes the substantially water-soluble material without any pharmaceutically acceptable excipients.
  • Embodiments of the pharmaceutical composition may include one or more of the following features.
  • the benzimidazole compound may be selected from one or more of omeprazole, lansoprazole, pantoprazole, rabeprazole, and single enantiomers thereof.
  • the one or more pharmaceutically acceptable excipients may be selected from one or more diluents, disintegrants, binders and lubricants.
  • the diluent may be selected from one or more of sugars, sugar alcohols, cellulose derivatives, and starches.
  • the sugar may be selected from dextrose, glucose and lactose.
  • the sugar alcohol may be selected from sorbitol, xylitol and mannitol.
  • the cellulose derivative may be selected from powdered cellulose and microcrystalline cellulose.
  • the starch may be selected from corn starch, pregelatinized starch, and maize starch.
  • the disintegrant may be selected from one or more of sodium starch glycolate, croscarmellose sodium, and corn starch.
  • the binder may be selected from one or more of cellulose derivatives, gums, water- soluble vinylpyrrolidone polymers, and sugars.
  • the cellulose derivatives may be one or more of hydroxypropylmethyl cellulose, hydroxypropyl cellulose and methylcellulose.
  • the gums may be one or more of xanthan gum, gum acacia and tragacantli.
  • the water-soluble vinylpyrrolidone polymers may be one or more of polyvinylpyrrolidone and copolymers of vinylpyrrolidone and vinyl acetate.
  • the sugars may be one or more of sorbitol and mannitol.
  • the lubricant may be one or more of magnesium stearate, talc, sodium stearyl fumarate, and colloidal silicon dioxide.
  • the substantially water-soluble material may be one or more of a substantially water-soluble polymer and a substantially water-soluble excipient.
  • the water-soluble polymer may be selected from one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, sodium alginate, sodium carboxymethyl cellulose, and copolymer of vinylpyrrolidone and vinyl acetate.
  • the water- soluble excipient may be one or more of lactose, mannitol, sorbitol, sucrose and glucose.
  • the core may include the substantially water-soluble material without any pharmaceutically acceptable excipients.
  • the separating layer may include the substantially water-soluble material without any pharmaceutically acceptable excipients.
  • a stable oral benzimidazole pharmaceutical composition includes a core and an enteric coating.
  • the core contains a benzimidazole compound, a substantially water-soluble material, and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is not alkaline.
  • the enteric coating surrounds and is directly in contact with the core.
  • the formulation is devoid of a separating layer between the core and the enteric coating.
  • Embodiments of the pharmaceutical composition may include one or more of the following features.
  • the benzimidazole compound may be selected from one or more of omeprazole, lansoprazole, pantoprazole, rabeprazole, and single enantiomer thereof.
  • the one or more pharmaceutically acceptable excipients of the core may be selected from one or more of diluents, disintegrants, binders, and lubricants.
  • the diluent may be selected from one or more of sugars, sugar alcohols, cellulose derivatives, and starches.
  • the sugar may be selected from dextrose, glucose and lactose.
  • the sugar alcohol may be selected from sorbitol, xylitol, and mannitol.
  • the cellulose derivative may be selected from powdered cellulose and macrocrystalline cellulose.
  • the starch may be selected from corn starch, pregelatinized starch, and maize starch.
  • the disintegrant may be selected from one or more of sodium starch glycolate, croscarmellose sodium, and corn starch.
  • the binder may be selected from one or more of cellulose derivatives, gums, water- soluble vinylpyrrolidone polymers, and sugars.
  • the cellulose derivatives may be one or more of hydroxypropylmethyl cellulose, hydroxypropyl cellulose and methylcellulose.
  • the gums may be one or more of xanthan gum, gum acacia and tragacanth.
  • the water-soluble vinylpyrrolidone polymers may be one or more of polyvinylpyrrolidone and copolymers of vinylpyrrolidone and vinyl acetate.
  • the sugars may be one or more of sorbitol and mannitol.
  • the lubricant may be one or more of magnesium stearate, talc, sodium stearyl fumarate, and colloidal silicon dioxide.
  • a process for the preparation of a stable oral benzimidazole pharmaceutical composition includes preparing a core, coating the core with a separating layer, and coating either the core or the separating layer with an enteric layer.
  • the core is prepared by dispersing a benzimidazole compound, a substantially water-soluble material and, optionally, one or more pharmaceutically acceptable excipients in an aqueous medium to obtain a dispersion, spray drying the dispersion, and mixing with the one or more optional pharmaceutically acceptable excipients and compressing.
  • the core is coated with a separating layer formed by a substantially water soluble material and, optionally, pharmaceutically acceptable excipients. At least one of the core and the separating layer includes the substantially water-soluble material without any pharmaceutically acceptable excipients.
  • Embodiments of the process may include one or more of the following features.
  • the benzimidazole compound may be selected from one or more of omeprazole, lansoprazole, pantoprazole, rabeprazole, and single enantiomers thereof.
  • the one or more pharmaceutically acceptable excipients of the core may be selected from one or more of diluents, disintegrants, binders, and lubricants.
  • the diluent may be selected from one or more of sugars, sugar alcohols, cellulose derivatives, and starches.
  • the disintegrant may be selected from one or more of sodium starch glycolate, croscarmellose sodium, and corn starch.
  • the binder may be selected from one or more of cellulose derivatives, gums, water-soluble vinylpyrrolidone polymers, and sugars.
  • the lubricant may be one or more of magnesium stearate, talc, sodium stearyl fumarate, and colloidal silicon dioxide.
  • a method inhibiting gastric acid secretion includes administering a pharmaceutical composition that includes (a) a core comprising a benzimidazole compound, a substantially water-soluble material and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is not alkaline; (b) a separating layer surrounding the core and comprising a substantially water-soluble material and, optionally, one or more pharmaceutically acceptable excipients, and (c) an enteric coating surrounding the separating layer. At least one of the core and the separating layer includes the substantially water-soluble material without any pharmaceutically acceptable excipients.
  • Embodiments of the method may include one or more of the following features or any of the features described herein.
  • the benzimidazole compound may be selected from one or more of omeprazole, lansoprazole, pantoprazole, rabeprazole, and single enantiomers thereof.
  • a method inhibiting gastric acid secretion may include one or more of the following features or any of the features described herein.
  • the method includes administering a pharmaceutical composition that includes (a) a core containing a benzimidazole compound, a substantially water-soluble material, and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is not alkaline, and (b) an enteric coating surrounding and directly in contact with the core, wherein the formulation is devoid of a separating layer between the core and the enteric coating.
  • a pharmaceutical composition that includes (a) a core containing a benzimidazole compound, a substantially water-soluble material, and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is not alkaline, and (b) an enteric coating surrounding and directly in contact with the core, wherein the formulation is devoid of a separating layer between the core and the enteric coating.
  • the benzimidazole compound maybe selected from one or more of omeprazole, lansoprazole, pantoprazole, rabeprazole, and single enantiomers thereof.
  • the inventors In seeking to develop stable benzimidazole dosage forms, the inventors have developed a number of stable dosage forms and processes for their preparation. For example, the inventors have developed a stable benzimidazole dosage form that includes a core, a separating layer, and an enteric coating.
  • the core includes a benzimidazole compound, a water-soluble material, and optional pharmaceutically accepted excipients.
  • the core is characterized as not being alkaline.
  • the separating layer is deposited or otherwise coated on the core and includes a water-soluble material and, optionally, one or more pharmaceutically accepted excipient.
  • the enteric coating surrounds the separating layer. At least one of the core or the separating layer has a water-soluble material without additional pharmaceutically acceptable excipients.
  • the inventors also have developed a stable benzimidazole dosage form that includes a core and an enteric coating that is deposited or otherwise coated directly on the core.
  • the core contains a benzimidazole compound, a water-soluble material and, optionally, one or more pharmaceutically acceptable excipients.
  • the core is characterized as being not alkaline.
  • One process to formulate the stable benzimidazole formulation includes preparing a core and coating the core.
  • a benzimidazole compound a water-soluble material and, optionally, one or more pharmaceutically acceptable excipients are dispersed in purified water to obtain a dispersion.
  • the dispersion is spray dried, mixed with optional pharmaceutically acceptable excipients, and compressed to form cores.
  • the core then is coated with a separating layer that is formed from substantially water-soluble material and optional pharmaceutically acceptable excipients.
  • the coated core then is coated with an enteric coating. Alternatively, the cores may be enteric coated without including the separating layer.
  • Suitable benzimidazole compounds include any substituted benzimidazole compound that is capable of inhibiting gastric acid secretion by any mechanism and thus having utility in treating various gastrointestinal disorders.
  • the benzimidazole compounds may include, for example, one or more of omeprazole, lansoprazole, rabeprazole, pantoprazole, leminoprazole, pariprazole, single enantiomers thereof, pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
  • the benzimidazole compounds may be in the crystalline or amorphous salt form.
  • the amount of benzimidazole compound may vary from about 1% to about 80%, and preferably from about 5% to about 35% based on the weight of the formulation.
  • the core as used herein refers to any structure that is enclosed or surrounded by a separating coating or equivalent, or where the separating coating is absent, enclosed or surrounded by an enteric coating.
  • the core may be in the form of a tablet, pellet, capsule, powder or mixture thereof.
  • the term 'tablet' as used herein may include one or more of minitablets, microtablets, or tablets.
  • the term 'pellets' as used herein may include one or more of granules, beads, pellets, slugs or mixtures thereof.
  • the core is preferably non- alkaline.
  • the core may contain one or more pharmaceutically acceptable excipients, including one or more of binders, diluents, disintegrants, lubricants/glidants and solubilizers/wetting agents.
  • the benzimidazole compound in the core may be amorphous or crystalline.
  • the benzimidazole compound may also be spray dried with water soluble polymers and incorporated in the core.
  • the core may contain one or more pre-layers of water soluble polymers between the inert nucleus and drug containing layer. These one or more pre-layers are different from the separating layer (or subcoat).
  • Suitable diluents include one or more of sugars, such as dextrose, glucose, and lactose; sugar alcohols such as sorbitol, xylitol, and mannitol; cellulose derivatives such as powdered cellulose and microcrystalline cellulose; starches such as corn starch, pregelatinized starch, and maize starch.
  • sugars such as dextrose, glucose, and lactose
  • sugar alcohols such as sorbitol, xylitol, and mannitol
  • cellulose derivatives such as powdered cellulose and microcrystalline cellulose
  • starches such as corn starch, pregelatinized starch, and maize starch.
  • the preferred range of diluents in the formulation depends on the type of formulations to be prepared as disclosed in the various examples contained herein.
  • Suitable binders include one or more of cellulose derivatives such as hydroxypropylmethyl cellulose, hydroxypropyl cellulose, and methylcellulose; gums such as xanthan gum, gum acacia, and tragacanth; water-soluble vinylpyrrolidone polymers such as polyvinylpyrrolidone and copolymers of vinylpyrrolidone and vinyl acetate; and sugars such as sorbitol, mannitol or such like.
  • the preferred range of binders in the formulation depends on the type of formulations to be prepared as disclosed in various examples contained herein.
  • Suitable disintegrants may include one or more of sodium starch glycolate, croscarmellose sodium, corn starch, and other suitable disintegrants.
  • Suitable wetting agents include one or more of sodium lauryl sulphate, polysorbate 80, and equivalents.
  • Suitable lubricants/glidants include one or more of magnesium stearate, talc, sodium stearyl fumarate, colloidal silicon dioxide and equivalents. The preferred ranges of disintegrants, wetting agents, and lubricants/glidants in the formulation depends on the type of formulations to be prepared as disclosed in various examples contained herein.
  • the separating layer refers to the layer that separates the core from the enteric coating.
  • the separating layer is made up of substantially water soluble materials which is capable of dissolving or forming a gel upon or after contact with water. Such materials may include substantially water-soluble polymers and/or substantially water-soluble excipients.
  • the capsule shell acts as a separating layer, an additional application of one or more separating layers is optional.
  • the enteric coating can directly be layered on the capsule shell in such a formulation.
  • the substantially water-soluble excipients may be selected from glucose, lactose, mannitol, sorbitol, sucrose, dextrose or equivalents.
  • the substantially water-soluble polymers may be selected from hydroxypropylmethylcellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, sodium alginate, sodium carboxymethyl cellulose, copolymer of vinylpyrrolidone and vinyl acetate.
  • such polymers are hydroxypropylmethylcellulose, hydroxypropyl cellulose or polyvinylpyrrolidone.
  • the range of the substantially water-soluble polymers in the formulation depends on the type of formulations prepared and will be apparent to one skilled in the art based on the various examples disclosed in the specification.
  • the enteric coating may include one or more of cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, methacrylic acid methyl esters/methacrylic acid copolymers, such as compounds known under the trademarks of EudragitNE30D, Eudragit L, Eudragit S, Eudragit L 100 55 and marketed by Rohm Pharma, and mixtures thereof.
  • the enteric coating may also contain plasticizers such as triacetin, triethyl citrate, tributyl sebecate, diethyl phthalate, polyethylene glycol and inert excipients such as talc, titanium dioxide, colloidal silicon dioxide, hydroxypropyl methylcellulose, crospovidone and the like.
  • plasticizers such as triacetin, triethyl citrate, tributyl sebecate, diethyl phthalate, polyethylene glycol and inert excipients such as talc, titanium dioxide, colloidal silicon dioxide, hydroxypropyl methylcellulose, crospovidone and the like.
  • PNP-K30/HPC-L/HPMC/Mannitol (one or mixtures there of) was dissolved in water, and to this ammonium hydroxide was added.
  • omeprazole was added and dispersed.
  • the dispersion was applied to the inert tablet using a conventional coating machine.
  • the benzimidazole tablets thus prepared were coated with suitable polymer/excipient using a conventional coating machine. Finally, the tablets were enteric coated with the enteric layer formulation.
  • Acryl EZE TM is a registered trademark of Colorcon and is a type of ready-to-disperse enteric coating formulation.
  • HPMC/HPC-L was dissolved in water and applied on Non Pariel seeds.
  • HPC-L/Mannitol was dissolved under stirring in purified water.
  • ammonium hydroxide was added, with continuous stirring.
  • Esomeprazole was dispersed in the mixture thus prepared under constant stirring.
  • the non-pariel seeds were coated with the esomeprazole dispersion in a Fluid Bed Processor to form pellets. The pellets then were coated with suitable polymer/excipient and then enteric material using a Fluid Bed Processor.
  • PNP-K30/HPC-L/HPMC was dissolved in water and to this ammonium hydroxide was added.
  • rabeprazole was added and dispersed. The dispersion was applied on inert tablet using conventional coating machine.
  • Prepared benzimidazole tablets were coated with suitable polymer using conventional coating machine. The tablets then were enteric coated with Acryl EZE. Multiple tablets were filled in hard gelatin capsules.
  • Hydroxypropyl methylcellulose was dissolved in water followed by dispersion of talc and titanium dioxide. 2. The drug-layered pellets were loaded in fluid bed processor followed by coating with the solution of step 1 above. Enteric coating Preparation of Hydroxypropyl methylcellulose phthalate coating dispersion:
  • step 3 The dispersion of step 1 was added to the dispersion of step 2 followed by water addition and mixing.
  • the barrier-coated pellets were coated with the above enteric coating dispersion and the enteric-coated pellets were filled in hard gelatin capsules.
  • Example 5 The procedure described above for Example 4 was followed for Example 5.
  • Hydroxypropyl methylcellulose was dissolved in water followed by dispersion of lansoprazole.
  • Hydroxypropyl methylcellulose was dissolved in water followed by dispersion of talc and titanium dioxide.
  • step 2 The dispersion of step 1 above was added to the Methacrylic acid:Ethylacrylate copolymer dispersion and stirred for 30 min.
  • the barrier-coated pellets were coated with the above enteric coating dispersion and the enteric-coated pellets were filled into hard gelatin capsules.
  • Hydroxypropyl cellulose was dissolved in water and sprayed on non-pariel seeds. Hydroxypropyl cellulose was dissolved under stirring in purified water and then ammonium hydroxide was added under continued stirring. Then omeprazole was dispersed in a prepared mixture under constant stirring. Non-pariel seeds were coated with omeprazole dispersion in a Fluid Bed Processor to obtain pellets. The pellets thus prepared were coated with mannitol followed by the enteric coating formulation using a Fluid Bed Processor. Finally, the pellets were blended with colloidal silicon dioxide and filled into hard gelatin capsules.
  • Hydroxypropyl cellulose and polyethylene glycol 6000 were dissolved in water. Talc was dispersed in the above solution and the resulting dispersion was sprayed on to non-pariel seeds.
  • Hydroxypropyl cellulose was dissolved under stirring in purified water followed by the addition of ammonium hydroxide under continued stirring.
  • Omeprazole was dispersed onto the above prepared mixture under constant stirring. The above dispersion then was sprayed onto non-pariel seeds in a fluid bed processor to obtain pellets.
  • the pellets were coated with mannitol/HPC/HPMC followed by the enteric coating formulation using a fluid bed processor. Finally, the pellets were blended with colloidal silicon dioxide and filled into hard gelatin capsules.
  • Acryl EZE TM is a registered trademark of Colorcon and is a type of ready-to-disperse enteric coating formulation.
  • Mannitol and PNP-K30/HPC-L HPMC were dissolved in water, and to this ammonium hydroxide was added.
  • omeprazole was added and dispersed.
  • the dispersion then was spray dried and the spray dried granules were mixed with Pearlitol, lubricated with sodium stearyl fumarate to form a blend, and the blend was compressed into tablets.
  • the benzimidazole tablets thus prepared were coated with suitable polymer/excipient using a conventional coating machine.
  • the tablets then were enteric coated with the enteric coating formulation.
  • Example 10 Enteric-coated minitablets containing pantoprazole.
  • Pantoprazole and Hydroxypropyl methylcellulose were mixed and granulated with purified water to obtain a wet mass. 2. The wet mass was passed through 30-mesh screen.
  • Hydroxypropyl methylcellulose (for coating) was dissolved in purified water.
  • step 4 The screened mass of step 2 was loaded in a Fluid bed processor and the solution of step 3 was sprayed onto it to obtain coated pantoprazole.
  • Compression 1 The coated Pantoprazole, Mannitol, Microcrystalline cellulose and Crospovidone were mixed in suitable blender.
  • step 6 was compressed into tablets.
  • Enteric coating Preparation of Hydroxypropyl methylcellulose phthalate coating dispersion:
  • step ( 1 ) was added to dispersion of step (2) followed by water addition and mixing.
  • the tablets thus produced were enteric coated with enteric coating dispersion and suitable numbers of tablets as per desired dosage were optionally filled into hard gelatin capsule.
  • nonessential ingredients optionally can be added to the blend or mixture for cosmetic, aesthetic and/or manufacturing purposes. These include colorants, diluents, lubricants, and glidants. Further, it is contemplated that any single feature or any combination of optional features of the inventive variations described herein may be specifically excluded from the claimed invention and be so described as a negative limitation. Accordingly, it is not intended that the invention be limited, except as by the appended claims.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions orales stables de benzimidazole et leurs procédés de préparation. L'invention concerne également une composition pharmaceutique orale stable de benzimidazole comprenant un noyau, une couche de séparation et un enrobage gastrorésistant. Le noyau renferme un composé de benzimidazole, un matériau sensiblement hydrosoluble et, éventuellement, un ou plusieurs excipients de qualité pharmaceutique, le noyau n'étant pas alcalin. La couche de séparation entoure le noyau et renferme un matériau sensiblement hydrosoluble et, éventuellement, un ou plusieurs excipients de qualité pharmaceutique. L'enrobage gastrorésistant entoure la couche de séparation. Le noyau et/ou la couche de séparation renferme le matériau sensiblement hydrosoluble, mais pas d'excipients de qualité pharmaceutique.
EP04707268A 2003-01-31 2004-02-02 Compositions orales stables de benzimidazole et leurs procedes de preparation Withdrawn EP1594479A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN80DE2003 2003-01-31
INDE00802003 2003-01-31
INDE07282003 2003-05-27
IN728DE2003 2003-05-27
PCT/IB2004/000235 WO2004066982A1 (fr) 2003-01-31 2004-02-02 Compositions orales stables de benzimidazole et leurs procedes de preparation

Publications (1)

Publication Number Publication Date
EP1594479A1 true EP1594479A1 (fr) 2005-11-16

Family

ID=32827126

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04707268A Withdrawn EP1594479A1 (fr) 2003-01-31 2004-02-02 Compositions orales stables de benzimidazole et leurs procedes de preparation

Country Status (2)

Country Link
EP (1) EP1594479A1 (fr)
WO (1) WO2004066982A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
WO2006067599A2 (fr) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Compositions orales stables de benzimidazoles et leur procede de preparation
EP1785135A1 (fr) * 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. Nouvelles compositions galéniques stabilisées comprenant du lanzoprazole et leur préparation
JP2009519334A (ja) * 2005-12-20 2009-05-14 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール経口崩壊錠剤
WO2008062320A2 (fr) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Formulations à libération prolongée d'un inhibiteur de la pompe à protons
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US6207198B1 (en) * 1995-09-21 2001-03-27 Schwarz Pharma Ag Composition containing an acid-labile omeprazole and process for its preparation
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
EP1108425B1 (fr) * 1999-12-16 2005-06-08 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. Nouvelles préparations pharmaceutiques multi-unitaires stables contenant des benzimidazoles substitués
WO2002032427A1 (fr) * 2000-10-20 2002-04-25 Galephar M/F Formulation stable administrable par voie orale contenant un derive de benzimidazole
WO2003103638A1 (fr) * 2002-06-07 2003-12-18 Geneva Pharmaceuticals, Inc. Compositions pharmaceutiques stabilisees contenant des composes de benzimidazole

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004066982A1 *

Also Published As

Publication number Publication date
WO2004066982A1 (fr) 2004-08-12
WO2004066982A8 (fr) 2005-08-25

Similar Documents

Publication Publication Date Title
JP4907765B2 (ja) 経口医薬パルス放出剤形
RU2214232C2 (ru) Пероральная фармацевтическая лекарственная форма с продолжительным высвобождением
JP3878669B2 (ja) プロトンポンプ抑制剤を含有する複数単位の製剤
US7544370B2 (en) Pantoprazole multiparticulate formulations
US20020064555A1 (en) Proton pump inhibitor formulation
JP2002523443A (ja) オメプラゾール製剤
US6733778B1 (en) Omeprazole formulation
JP2002532425A (ja) 新規な医薬製剤
US20080003281A1 (en) Modified Release Tablet Formulations for Proton Pump Inhibitors
WO2011140446A2 (fr) Formulations pharmaceutiques
WO2014016754A2 (fr) Compositions pharmaceutiques d'inhibiteur de la pompe à protons
CA2565083C (fr) Nouvelle forme posologique pharmaceutique et procede de fabrication
US20060024362A1 (en) Composition comprising a benzimidazole and process for its manufacture
EP1594479A1 (fr) Compositions orales stables de benzimidazole et leurs procedes de preparation
WO2012010944A2 (fr) Composition sous forme de comprimé à plusieurs unités
AU2007311493B2 (en) Multiple unit tablet compositions of benzimidazole compounds
WO2005051362A2 (fr) Compositions stables de benzimidazole a administration orale et leurs procedes de preparation
US8658216B2 (en) Stable oral benzimidazole compositions and process of preparation thereof
US8911787B2 (en) Stable oral benzimidazole compositions and process of preparation thereof
CN101524336B (zh) 含有泮托拉唑作为活性成分的剂型
WO2010018593A2 (fr) Composition de comprimé de benzimidazole à unités multiples résistante à l'acide gastrique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050831

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1088815

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090901

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1088815

Country of ref document: HK